Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 8-K (Current Report)
Date of Report: February 19, 2025 (Event Date: February 20-21, 2025)
Reporting Period: The filing covers the entry into a material definitive agreement and the closing of an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial results. Key metrics include:
- Shares Sold: 1,500,000 total shares (1,304,348 Base Shares + 195,652 Option Shares).
- Offering Price: $2.00 per share.
- Gross Proceeds: $3.0 million.
- Underwriting Discount: 8.0% of the public offering price.
- Management Fee: 1.0% of aggregate gross proceeds.
- Expense Reimbursement: Up to $145,000.
- Representative Warrants: 75,000 unregistered warrants issued to the representative with an exercise price of $2.50 per share, expiring February 20, 2030.
- Post-Offering Outstanding Shares: 6,778,837 shares.
- Use of Proceeds: Working capital and general corporate purposes.
Note: The filing does not provide data on revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the increase in outstanding common stock and the influx of gross proceeds from the public offering. The company moved from a pre-offering capital structure to one with 6,778,837 shares outstanding immediately following the full exercise of the over-allotment option on February 21, 2025.
Outlook, Risks, and Contingencies
- Management Commentary: The Company intends to utilize net proceeds for working capital and general corporate purposes.
- Unregistered Securities: The Representative Warrants were issued pursuant to exemptions under Section 4(a)(2) of the Securities Act and Regulation D, meaning they are not registered under the Securities Act of 1933.
- Legal Opinions: The legality of the issuance was confirmed by ArentFox Schiff LLP.
- Risks: The filing notes that representations and warranties in the Underwriting Agreement are subject to limitations and are for the benefit of the contracting parties only.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 8.0% underwriting discount, 1.0% management fee, and reimbursable expenses.
- Confirm the dilution impact on existing shareholders given the increase to 6,778,837 outstanding shares.
- Review the terms of the 75,000 Representative Warrants (exercise price $2.50, expiration 2030) for potential future dilution.
- Check subsequent filings for the actual deployment of the $3.0 million gross proceeds.